Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient.
Fiche du document
- doi: 10.1093/jac/dkh310
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/jac/dkh310
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/15175271
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/0305-7453
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7A37F4C59DB82
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Therapy Treatments for diseases Medical treatment Therapy Treatment of diseases Pneumonitis Lungs--InflammationCiter ce document
C. Robatel et al., « Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. », Serveur académique Lausannois, ID : 10.1093/jac/dkh310
Métriques
Partage / Export
Résumé
OBJECTIVES: To determine whether voriconazole dosage adjustment is required during continuous veno-venous haemodiafiltration (CVVHDF). METHODS: Voriconazole pharmacokinetics were studied in a critically ill patient under CVVHDF. The analysis was carried out for 12 h following a 6 mg/kg dose. Voriconazole concentrations were measured by HPLC in blood inlet and outlet lines and in dialysate. RESULTS: The total body clearance of voriconazole was 20.3 L/h, with a terminal half-life of 13.7 h and a distribution volume of 399 L. The estimated sieving coefficient was 0.53 and the filtration-dialysis clearance 1.2 L/h. CONCLUSIONS: CVVHDF does not significantly affect voriconazole disposition and requires no dosage adjustment.